155 related articles for article (PubMed ID: 23199511)
1. Mechanisms of the antitumoural effects of aspirin in the gastrointestinal tract.
Bruno A; Dovizio M; Tacconelli S; Patrignani P
Best Pract Res Clin Gastroenterol; 2012 Aug; 26(4):e1-e13. PubMed ID: 23199511
[TBL] [Abstract][Full Text] [Related]
2. Mode of action of aspirin as a chemopreventive agent.
Dovizio M; Bruno A; Tacconelli S; Patrignani P
Recent Results Cancer Res; 2013; 191():39-65. PubMed ID: 22893199
[TBL] [Abstract][Full Text] [Related]
3. Beyond COX-1: the effects of aspirin on platelet biology and potential mechanisms of chemoprevention.
Ornelas A; Zacharias-Millward N; Menter DG; Davis JS; Lichtenberger L; Hawke D; Hawk E; Vilar E; Bhattacharya P; Millward S
Cancer Metastasis Rev; 2017 Jun; 36(2):289-303. PubMed ID: 28762014
[TBL] [Abstract][Full Text] [Related]
4. Wondering how the wonder drug works.
Kaiser J
Science; 2012 Sep; 337(6101):1472. PubMed ID: 22997321
[No Abstract] [Full Text] [Related]
5. Clinical pharmacology of cyclooxygenase inhibition and pharmacodynamic interaction with aspirin by floctafenine in Thai healthy subjects.
Maenthaisong R; Tacconelli S; Sritara P; Del Boccio P; Di Francesco L; Sacchetta P; Archararit N; Aryurachai K; Patrignani P; Suthisisang C
Int J Immunopathol Pharmacol; 2013; 26(2):403-17. PubMed ID: 23755755
[TBL] [Abstract][Full Text] [Related]
6. Theoretical investigation of aspirin dosage regimen to exhibit optimal antiplatelet effects and decrease risk of upper gastrointestinal lesions.
Yokoyama H; Yaguchi T; Suzuki Y; Tokuoka K; Watanabe M; Kitagawa Y; Yamada Y
Biol Pharm Bull; 2012; 35(12):2112-8. PubMed ID: 23047244
[TBL] [Abstract][Full Text] [Related]
7. Short-term exposure of platelets to glucose impairs inhibition of platelet aggregation by cyclooxygenase inhibitors.
Kobzar G; Mardla V; Samel N
Platelets; 2011; 22(5):338-44. PubMed ID: 21557683
[TBL] [Abstract][Full Text] [Related]
8. Gallic acid, a dietary polyphenolic component, blunts the inhibition of platelet COX-1 by aspirin: preliminary in-vitro findings.
Crescente M; Cerletti C; de Gaetano G
Thromb Haemost; 2007 Jun; 97(6):1054-6. PubMed ID: 17549313
[No Abstract] [Full Text] [Related]
9. Unlocking Aspirin's Chemopreventive Activity: Role of Irreversibly Inhibiting Platelet Cyclooxygenase-1.
Lichtenberger LM; Fang D; Bick RJ; Poindexter BJ; Phan T; Bergeron AL; Pradhan S; Dial EJ; Vijayan KV
Cancer Prev Res (Phila); 2017 Feb; 10(2):142-152. PubMed ID: 27998883
[TBL] [Abstract][Full Text] [Related]
10. Human pharmacology of naproxen sodium.
Capone ML; Tacconelli S; Sciulli MG; Anzellotti P; Di Francesco L; Merciaro G; Di Gregorio P; Patrignani P
J Pharmacol Exp Ther; 2007 Aug; 322(2):453-60. PubMed ID: 17473175
[TBL] [Abstract][Full Text] [Related]
11. New Insights into the Mechanism of Action of Aspirin in the Prevention of Colorectal Neoplasia.
Di Francesco L; López Contreras LA; Sacco A; Patrignani P
Curr Pharm Des; 2015; 21(35):5116-26. PubMed ID: 26369679
[TBL] [Abstract][Full Text] [Related]
12. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance".
Santilli F; Rocca B; De Cristofaro R; Lattanzio S; Pietrangelo L; Habib A; Pettinella C; Recchiuti A; Ferrante E; Ciabattoni G; Davì G; Patrono C
J Am Coll Cardiol; 2009 Feb; 53(8):667-77. PubMed ID: 19232899
[TBL] [Abstract][Full Text] [Related]
13. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin.
Catella-Lawson F; Reilly MP; Kapoor SC; Cucchiara AJ; DeMarco S; Tournier B; Vyas SN; FitzGerald GA
N Engl J Med; 2001 Dec; 345(25):1809-17. PubMed ID: 11752357
[TBL] [Abstract][Full Text] [Related]
14. A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers.
Greenberg HE; Gottesdiener K; Huntington M; Wong P; Larson P; Wildonger L; Gillen L; Dorval E; Waldman SA
J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1509-15. PubMed ID: 11185674
[TBL] [Abstract][Full Text] [Related]
15. Cyclooxygenase-2 expression and recurrence of colorectal adenomas: effect of aspirin chemoprevention.
Benamouzig R; Uzzan B; Martin A; Deyra J; Little J; Girard B; Chaussade S;
Gut; 2010 May; 59(5):622-9. PubMed ID: 20427397
[TBL] [Abstract][Full Text] [Related]
16. Aspirin resistance.
Tantry US; Mahla E; Gurbel PA
Prog Cardiovasc Dis; 2009; 52(2):141-52. PubMed ID: 19732606
[No Abstract] [Full Text] [Related]
17. Cyclooxygenase expression and platelet function in healthy dogs receiving low-dose aspirin.
Dudley A; Thomason J; Fritz S; Grady J; Stokes J; Wills R; Pinchuk L; Mackin A; Lunsford K
J Vet Intern Med; 2013; 27(1):141-9. PubMed ID: 23278865
[TBL] [Abstract][Full Text] [Related]
18. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis.
Schrör K
Semin Thromb Hemost; 1997; 23(4):349-56. PubMed ID: 9263351
[TBL] [Abstract][Full Text] [Related]
19. Cyclooxygenase-1 haplotype C50T/A-842G does not affect platelet response to aspirin.
Pettinella C; Romano M; Stuppia L; Santilli F; Liani R; Davì G
Thromb Haemost; 2009 Apr; 101(4):687-90. PubMed ID: 19350112
[TBL] [Abstract][Full Text] [Related]
20. Cyclooxygenase Inhibitors and Cancer: The Missing Pieces.
Patrono C
J Pharmacol Exp Ther; 2023 Aug; 386(2):181-189. PubMed ID: 37280092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
